Real-World Data Study Shows Biosimilar Rituximab for Rheumatoid Arthritis Safe and Effective
A new real-world data (RWD) study published in Rheumatology International found that patients with rheumatoid arthritis who switched from Roche’s biosimilar rituximab to Rixathon’s version of the biosimilar did not suffer any deterioration. Patients who had not taken any version of rituximab also saw similar benefits.
New Data Shows Part D Savings Took Hit Due to Price Increases on RA Drugs
A new study published in JAMA Network Open suggests patients took a big hit on savings for RA drugs under [...]
Advertisement
